3SOF

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3
   

AVI BioPharma gets Defense Dept. swine flu pact
AVI BioPharma says it will get up to $5.1M from government to work on swine flu treatments

CORVALLIS, Ore. (AP) -- AVI BioPharma Inc. says it will receive up to $5.1 million under a contract with the U.S. government to develop swine flu drugs.

AVI disclosed May 5 that it entered into the contract with the U.S. Defense Threat Reduction Agency, a section of the Department of Defense that focuses on chemical, biological, nuclear and other weapons. Under the contract, AVI will conduct preclinical development of at least one drug candidate and demonstrate it is effective by testing it on animals.

The company said it will analyze the swine flu to determine the most promising potential drugs, and make enough material to perform its tests.

AVI BioPharma Joining Russell 3000 Index...

AVI BioPharma, Inc. (NASDAQ:AVII - News), a developer of RNA-based drugs, today announced that immediately following the close of the U.S. markets today it will join the broad-market Russell 3000� Index following Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes.

The annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000� Index or small-cap Russell 2000� Index as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. The Russell 3000 also serves as the U.S. component to the Russell Global Index, which Russell launched in 2007.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

Contact:
AVI Press and Investor Contact:Julie [email protected](541) 224-2575

Look at this amazing...
http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=AVII&mkttype=after

52wk Range: 0.45 - 1.98
Volume: 12,139,536
Avg Vol (3m): 875,382

Technicals
Last Price Quote is:
21.34%above 13-day MA
49.52%above 50-day MA
RS Rating: 96 

Fundamentals
Key Data:
Market Cap (M): $131.04 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/10/2009
Last Analyst Rating: Buy

From the looks of this chart we have a nice looking
Cup and Handel...BreakOUT !

updated chart scene...

updated chart look...


52wk Range: 0.45 - 2.26
Volume: 2,511,707
Avg Vol (3m): 1,150,010

Technicals
Last Price Quote is:
22.32%above 13-day MA
43.97%above 50-day MA
RS Rating: 97 

Fundamentals
Earnings Expected on Aug 10

Key Data:
Market Cap (M): $163.58 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/10/2009
Last Analyst Rating: Buy

Is Your Portfolio Ready for Second-Half Swine Flu Hysteria?

The death count is trending upwards and tensions over vaccines are growing - we could be in for a flu-crazed second half.

In an unnerving report today, the World Health Organization (WHO) announced that it will stop counting the individual cases of swine flu. The institution, composed of health officials from 193 nations across the globe, explained that the virus is spreading too rapidly in some areas of the world to count. According to the Centers for Disease Control's website, as of July 10, 37,246 cases have led to 211 deaths in the United States. Britain, meanwhile, estimates that its own case count escalated by 55,000 in the last week, according to the Associated Press. As warned by WHO head Dr. Margaret Chan back in May, a mutated, more dangerous form of the virus could break out this fall.

So what does all this mean for your portfolio? An Oxford Economics report released today suggests that the pandemic, made official on June 11, could lead to a -5% drop in the U.K.'s GDP over the next six months. Yesterday, President Obama committed $1.8 billion taxpayer dollars to an H1N1 emergency fund, to be used on vaccine ingredients and immunization campaigns.

Investors can follow vaccine related market-moves with the Swine Flu and Bird Flu Stocks Index. The Index is composed of vaccine-specific small-caps like Hemispherx BioPharma (AMEX: HEB - News) and Novavax (NASDAQ: NVAX - News), as well as diversified pharmaceutical giants GlaxoSmithKline (NYSE: GSK - News) and Novartis (NYSE: NVS - News). All 19 components have operations devoted specifically to the treatment, immunization, or prevention of the H1N1 virus.

An Associated Press article published yesterday warns that the fight over vaccines could get ugly when governments face the moral obligation of immunizing their own citizens before honoring international contracts. U.S. based Baxter International (NYSE: BAX - News) currently has orders from five countries for 80 million doses. According to a Reuters report yesterday, the Illinois-based company said it will have the H1N1 vaccine ready to ship by late-July or early-August, but it has stopped taking orders.

Elsewhere on the home front, Alabama-based BioCryst Pharmaceuticals (NASDAQ: BCRX - News) announced today that the intravenous form of its peramivir drug is not inferior to well-known Tamiflu, made by Roche (OTC: RHHBY - News). BioCryst stock is now up by 190% in the last three months, one of six in the Index that have more than doubled over the period.

Other North American players, AVI Biopharma (NASDAQ: AVII - News) and Alpha Pro Tech (AMEX: APT - News) have shot up by over 120% in the last 90 days.

As of this writing, the Swine Flu and Bird Flu Stocks Index is in the top-100 performing tickerspy Indexes over the last month, gaining 5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Fun and informative, tickerspy.com is a free investing website where you can track multiple stock portfolios and compare against 250 proprietary Indexes tracking themes from nanotech to agriculture to precious metals. Best of all, tickerspy.com lets you spy on the portfolios of nearly 3,000 Wall Street institutions and hedge funds and see graphs of their performance. Try tickerspy.com today and find out how you stack up against investing legends like Warren Buffett!

updated chart look...

updated chart look...
Looking foe a bounce off the 50-day MA

updated chart look...
Took a pullback, let's see what takes place now.

BreakOut... 
Cup with Handle ! 

updated chart look...